milrinone


Also found in: Wikipedia.

milrinone

 [mil´rĭ-nōn]
a cardiotonic used in treatment of congestive heart failure.

milrinone

/mil·ri·none/ (mil´rĭ-nōn) a cardiotonic used in the treatment of congestive heart failure.

milrinone

Primacor® Cardiology A positive inotropic phosphodiesterase inhibitor that provides short-term benefit; it may have a deleterious effects on chronic heart failure. See PROMISE trial.

milrinone

A PHOSPHODIESTERASE INHIBITOR drug. A brand name is Primacor.

milrinone

a synthetic phosphodiesterase inhibitor compound, used to provide inotropic support to the failing myocardium.
References in periodicals archive ?
These patients typically demonstrated changes with milrinone treatment.
Used as a short-term treatment for life-threatening heart failure, intravenous milrinone is currently sold in the United States by three companies Baxter, Hikma and Pfizer.
We routinely used milrinone (phosphodiesterase inhibitor) and adrenaline as inotropes for termination of bypass.
Anti-psychotic treatment was discontinued and supportive care was initiated afterwards (biphasic positive airway pressure, dopamine, milrinone, furosemide, intravenous hydration and alkalinization), amantadine and bromocriptine were started.
Milrinone is a PDE3 inhibitor that leads to increased availability of cAMP, with resultant positive inotropic effects, peripheral vasodilatation, left ventricular afterload reduction and increased myocardial contractility.
Effect of bolus milrinone on hemodynamic variables and pulmonary vascular resistance in patients with severe left ventricular dysfunction: a rapid test for reversibility of pulmonary hypertrension.
Use of Milrinone has also been advocated, as it has vasodilatory properties for both the systemic and pulmonary circulation.
It includes milrinone, tolvaptan, nesiritide, levosimendan, tezosentan, low-dose dopamine, and ultrafiltration.
Por lo anterior es trasladada a la unidad de cuidados intensivos, en donde se le inicio manejo con milrinone y se adiciono vancomicina al manejo antibiotico.
Currently, in HF treatment the room for inotropic therapies such as dopamine, dobutamine, and milrinone is very limited by the mortality associated with long-term treatment with these drugs [115-117].